SETD2 and plasma cell myeloma: SETD2, critical for the treatment of multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL)42,43, has a cryptic pocket targeted by a highly selective compound, EZM0414, currently undergoing Phase I clinical trials.